Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (AU:ATH) ) just unveiled an announcement.
Alterity Therapeutics has announced the appointment of Ann Cunningham as a director of the company, effective 17 April 2026, in accordance with ASX disclosure rules. The initial director’s interest notice confirms that Cunningham holds no relevant interests in Alterity’s securities and has no related contracts at the time of her appointment, indicating no immediate change to the company’s ownership or governance-related share structure for existing stakeholders.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a biotechnology company focused on therapeutic development, as indicated by its name and ASX listing context. The company operates within the life sciences sector and is subject to Australian corporate and securities regulation, including disclosure requirements for directors’ interests under ASX listing rules.
Average Trading Volume: 5,614,265
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.